The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although it says studies aimed at getting US approval are on track to ...